DA-302168S

DRUG5 trials

Sponsors

Chendu DIAO Pharmaceutical Group CO., LTD.

Conditions

Overweight and ObesityType 2 Diabetes Mellitus

Phase 1

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

CompletedNCT06534320

Chendu DIAO Pharmaceutical Group CO., LTD.Overweight and Obesity

Start: 2024-04-18End: 2024-12-31Updated: 2025-04-15

A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

CompletedNCT06541730

Chendu DIAO Pharmaceutical Group CO., LTD.Overweight and Obesity

Start: 2024-08-30End: 2025-01-30Updated: 2025-04-16

Phase 2

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

CompletedNCT06953063

Chendu DIAO Pharmaceutical Group CO., LTD.Overweight and Obesity

Start: 2025-05-15End: 2025-12-15Updated: 2026-05-28

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

Not yet recruitingNCT07755150

Chendu DIAO Pharmaceutical Group CO., LTD.Type 2 Diabetes Mellitus

Start: 2026-08-30End: 2027-10-20Target: 272Updated: 2026-08-31

Phase 3

A Study of DA-302168S in Participants With Overweight/Obesity

RecruitingNCT07629544

Chendu DIAO Pharmaceutical Group CO., LTD.Overweight and Obesity

Start: 2026-06-19End: 2027-10-19Target: 840Updated: 2026-08-06